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a  b  s  t  r  a  c  t
Chronic  kidney  disease  (CKD)  is a progressive  pathological  condition  in  which  renal  function  deteriorates
in  time.  The  ﬁrst  diagnosis  of  CKD  is often  carried  out  in  general  care  attention  by  general  practitioners
by  means  of serum  creatinine  (CNN)  levels.  However,  it lacks  sensitivity  and thus,  there  is a need for
new  robust  biomarkers  to  allow  the detection  of  kidney  damage  particularly  in  early  stages.  Multivari-
ate  data  analysis  of plasma  concentrations  obtained  from  LC-QTOF  targeted  metabolomics  method  may
reveal metabolites  suspicious  of  being  either  up-regulated  or down-regulated  from  urea cycle,  arginine
methylation  and  arginine-creatine  metabolic  pathways  in  CKD  pediatrics  and  controls.  The  results  show
that citrulline  (CIT),  symmetric  dimethylarginine  (SDMA)  and  S-adenosylmethionine  (SAM)  are  inter-
esting  biomarkers  to support  diagnosis  by CNN:  early  CKD  samples  and  controls  were  classiﬁed  with
an  increase  in  classiﬁcation  accuracy  of  18%  when  using  these  4 metabolites  compared  to  CNN  alone.
These  metabolites  together  allow  classiﬁcation  of  the  samples  into  a deﬁnite  stage  of the  disease  with  an
accuracy of 74%,  being  the 90%  of  the misclassiﬁcations  one  level  above  or below  the  CKD  stage  set  by  the
nephrologists.  Finally,  sex-related,  age-related  and  treatment-related  effects  were studied,  to evaluate
whether  changes  in metabolite  concentration  could  be  attributable  to  these  factors,  and  to  correct  them
in case a  new  equation  is developed  with  these  potential  biomarkers  for the  diagnosis  and  monitoring  of
pediatric  CKD.
© 2017  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Chronic kidney disease (CKD) is a major worldwide public health
problem, affecting both children and adults, in which kidney func-
tion declines progressively. In clinical practice, different equations
based on creatinine (CNN) concentration are used to estimate the
glomerular ﬁltration rate (GFR). This value reﬂects kidney func-
tion and is useful for the diagnosis of CKD and for assigning the
stage or degree of the disease. Detection of CKD is considered a
priority for primary care, because early treatment of CKD and its
complications may  delay or prevent the development of end-stage
renal disease (ESRD) [1]. In clinical practice, one of the most com-
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monly used equation in pediatrics to diagnose the disease for the
ﬁrst time is the Schwartz formula which is based on height, serum
CNN concentration and k coefﬁcient [2], as shown in Eq. (1).
GFR (mL  min−1/1.73 m2) = k × Height (cm)/Serum creatinine (mg dL−1) (1)
k coefﬁcient has changed along the years, and is 0.45 for ﬁrst year
term infants, 0.55 for children and adolescent girls and 0.7 for ado-
lescent boys currently.
Even if CNN is the classic biomarker used for the assessment of
renal function in primary care attention, it has several drawbacks.
Indeed, it lacks sensitivity and often reveals kidney damage when
an important nephronic loss has already occurred. For that rea-
son, in several early CKD patients a proper diagnosis by the general
practitioner (GP) using the available CNN-based screening blood or
urine tests is not possible until the disease progresses or more spe-
ciﬁc tests like abdominal computed tomography scan, abdominal
https://doi.org/10.1016/j.jpba.2017.10.036
0731-7085/© 2017 Elsevier B.V. All rights reserved.
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ecography, kidney histopathology and immunohistochemistry or
renal scintigraphy are carried out by nephrologists [3].
It would be ideal for GPs to be able to carry out better screening
including more sensitive biomarkers for CKD in addition to CNN,
as it is estimated that the majority of the population visits their
GP within a 3-year period and can be subjected to screening [1].
Screening tests can be performed using either urine or blood bioﬂu-
ids. The utility of urinalysis is at times overestimated due to the
inaccuracies in quantitatively collection of urine [4]. For that rea-
son, blood analysis is preferred in children for diagnostic purposes.
Thus, there is a need for new biomarkers (in addition to CNN) to
be included in the equations used by GP in screening blood tests.
Indeed, an earlier diagnosis of CKD, a better approximation to the
CKD stage deﬁned by nephrologists, monitoring of the progres-
sion of the disease and evaluation of the response to therapy are
required. The early detection of CKD and the approximation of the
CKD stage due to the implementation of new biomarkers in the
screening tests carried out by GP would allow the early referral to
the nephrologist, often leading to a better outcome of the patient.
CKD is associated with alterations in multiple metabolic
pathways [5]. Arginine-creatine metabolic pathway, arginine
methylation and the urea cycle were suspicious to be affected in
pediatric patients with CKD and thus, some metabolites from these
metabolic pathways were expected to be increased or decreased
in comparison to control pediatric patients. It has to be taken
into account that depending on the metabolic pathways, differ-
ences in fold change concentration of metabolites can be lower or
higher. For instance, the concentration of metabolites in the central
metabolism is relatively constant. Concentrations of metabolites
present in secondary metabolism-related pathways may  differ
more in concentration, depending on environmental conditions.
Indeed, all biological systems are easily perturbed by a number
of intra-individual or inter-individual experimental or environ-
mental factors, such as age, diet, growth phase, media, nutrients,
pH, sex, and temperature, which should be taken into consider-
ation. This is known as induced biological variation [6]. Central
metabolic pathways include glucolysis, the pentose phosphate
pathway, the tricarboxylic acid cycle, anaplerotic reactions and
biosynthetic pathways of fatty acids and amino acids, and those
reactions not included in central metabolic pathways are consid-
ered intermediate or secondary metabolic pathways [7]. The urea
cycle is considered a central metabolic pathway, as it is part of argi-
nine biosynthesis metabolic pathway, whereas arginine-creatine
metabolic pathway and arginine methylation are not included in
the central metabolic pathway, and thus are considered secondary
metabolic pathways.
Metabolomics aims at studying the dynamic changes, interac-
tions and responses to stimuli of metabolites in different metabolic
pathways [8]. The feasibility of metabolomics for biomarker dis-
covery is supported by the assumption that metabolites play an
important role in biological systems and that diseases cause dis-
ruption of biochemical pathways [9]. It has to be taken into account
that each bioﬂuid contains a large number of metabolites with con-
centration levels that can vary by orders of magnitude. However,
from a biological point of view, metabolites present in high con-
centrations are not necessarily more important than those at low
concentrations [6].
For all these reasons, in addition to the careful planning of
experiments and analytical measurements, statistical and chemo-
metric pre-processing are essential. Indeed, chemometrics, deﬁned
as the art of extracting chemically relevant information from data
produced in chemical experiments, is indispensable to obtain con-
sistent information and discard irrelevant information [10].
The aim of this work has been to perform data analysis on the
plasma concentrations of 16 metabolites from arginine-creatine,
urea cycle and arginine methylation metabolic pathways in thirty-
two patients at different stages of CKD and twenty-four control
patients not suffering from CKD in order to ﬁnd new potential
biomarkers. These metabolites were selected because they were
suspicious of being altered in pediatrics with CKD and were mea-
sured by means of a recently developed ion-pairing LC-QTOF-MS
methodology targeted at these metabolites [11]. To turn these
measurements into scores, we used complementary chemometric
tools to extract the diagnostically relevant information that remain
unseen with the naked eye. We  have also identiﬁed the potential
biomarkers for early diagnosis of CKD and checked whether these
metabolites could be affected by age, sex or treatment received.
2. Material and methods
2.1. Chemicals and reagents
Acetonitrile used for both standard preparation and mobile
phase was  supplied by Scharlau (Sentmenat, Spain). In addi-
tion, LC–MS grade ammonium formate eluent additive from Fluka
Analytical, Sigma-Aldrich (Steinheim, Germany) and perﬂuoro-
heptanoic acid (PFHA) from Acros Organics (New Jersey, USA)
completed the mobile phase. Standard preparation required the use
of LC–MS grade methanol from Scharlau (Sentmenat, Spain), ultra-
high purity water obtained from pretreated tap water by means
of Elix reverse osmosis followed by a Milli-Q system from Milli-
pore (Bedford, MA,  USA) and chlorhydric acid, obtained from Merck
(Darmstadt, Germany) as well.
Amino acid and amino acid derivative standards were sup-
plied by different manufacturers. l-Cysteine (CYS), creatine
(CTN), betaine (BET) and reduced glutathione (GSH) were sup-
plied by TCI (Tokyo, Japan). l-Methionine (MET), l-arginine (ARG),
glycine (GLY), l-homocysteine (HCYS), S-adenosyl-l-homocysteine
(SAH), NG,NG′-dimethyl-l-arginine di(p-hydroxyazobenzene-p′-
sulfonate) (SDMA), NG,NG-dimethylarginine dihydrochloride
(ADMA), S-adenosyl-l-methionine (SAM) and citrulline (CIT)
were provided by Sigma-Aldrich (Steinheim, Germany). Fluo-
rochem (Hadﬁeld, UK) provided N,N-dimethylglycine (DMG) and
homoarginine (HARG) and creatinine (CNN) was  pursached from
Alfa Aesar (Karlsruhe, Germany). Finally, creatine-d3 H2O from
CDN Isotopes (Quebec, Canada) and SDMA-d6, and creatinine-d3
(methyl-d3) from Toronto Research Chemicals, TRC Canada (North
York, Canada), and glutathione-13C215N from Cambridge Isotope
Laboratories (Andover, MA,  USA) were used as internal standards.
Dithiothreitol obtained from Fisher Scientiﬁc (Pittsburgh, PA, USA)
was used as thiol reductant agent.
2.2. LC/QTOF method
Chromatographic analysis of plasma samples was  carried out on
an Agilent 1200 Series HPLC system coupled to Agilent 6530 Series
hybrid quadrupole time-of-ﬂight mass spectrometer (Agilent Tech-
nologies, Santa Clara, CA, USA). Agilent Jet Stream ESI was  used as
an ion source. Chromatographic separation and mass spectrometry
are further described in a previous work [11]. This validated ion-
pairing LC/QTOF methodology was  used to quantify 16 metabolites
from arginine-creatine metabolic pathway, arginine methylation
and urea cycle in these plasma samples: ADMA, ARG, BET, CIT, CYS,
CTN, CNN, DMG, GSH, GLY, HARG, HCYS, MET, SAH, SAM and SDMA.
It has to be noted that for the aminothiols (CYS, GSH and HCYS)
total concentrations were quantiﬁed by means of a reduction pro-
cess in sample treatment with dithiothreitol. Creatine-d3 was used
to correct the signal of GLY, CIT, DMG, BET, CYS and CTN, whereas
gluthatione-13C215N corrected GSH signal. Similarly, creatinine-d3
adjusted for the concentration of HCYS, ARG, MET, CNN and HARG,
and SDMA-d6 was  used for ADMA, SDMA, SAM and SAH adjust-
ment.
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Fig. 1. Chromatogram of a plasma sample containing extracted ion chromatograms in MS/MS mode for ADMA and SDMA, and in MS  mode for the rest of the analytes.
All the metabolites except for ADMA and SDMA were acquired
in MS mode, with a scan rate of 2.2 spectra s−1 in 50–1000 m/z
mass range. Taking into account that ADMA and SDMA are struc-
tural isomer compounds and elute at the same retention time,
MS/MS  mode with a scan rate of 3 spectra s−1 and a mass range
from 30 to 1000 m/z was used with a collision energy of 10 V,
which allows the detection of different ion products for each of
the analytes. The protonated form [M+H+] of the analytes was
detected for all the analytes in MS  mode, and the speciﬁc tran-
sitions 203.1503 > 46.0657 m/z  and 203.1503 > 172.1086 m/z were
monitorized for ADMA and SDMA, respectively in MS/MS  mode
(Table 1). Fig. 1 shows an example chromatogram of a plasma sam-
ple containing both MS  and MS/MS  extracted ion chromatograms.
Regarding EU’s decision 2002/657/CE proposed for the collec-
tion of identiﬁcation points, conﬁrmation of the presence of the
analytes in samples is possible with this methodology, as retention
time of each analyte and the accurate mass measurement of the
m/z  with an error less than 5 ppm are used [12].
2.3. Study samples
Thirty-two patients suffering from chronic kidney disease aged
3–17 years were recruited for this study according to the following
criteria: subjects were followed up in Cruces University Hospi-
tal and clinically stable at the time of the study. The exclusion
criteria include suffering from hepatopathy, anuria and/or insulin-
dependent diabetes mellitus. The glomerular ﬁltration rate (GFR)
for each patient was calculated in the Pediatric Nephrology Ser-
vice at Cruces University Hospital using Schwartz formula. Then,
patients were classiﬁed by nephrologists according to glomerular
Table 1
Retention times, accurate m/z  rations in MS and MS/MS  modes and the internal
standard (IS) used for signal correction for each examined analyte.
Compound RT (min) m/z IS
GLY 2.40 76.0393 Creatine-d3
CIT 2.43 176.1030 Creatine-d3
DMG  2.46 104.0706 Creatine-d3
BET 2.50 118.0865 Creatine-d3
CYS 2.52 122.0270 Creatine-d3
CTN 2.54 132.0768 Creatine-d3
GSH 2.59 308.0911 Glutathione-13C215N
HCYS 2.71 136.0427 Creatine-d3
ARG 3.08 175.1193 Creatinine-d3
MET  3.11 150.0583 Creatinine-d3
CNN 3.23 114.0667 Creatinine-d3
HARG 3.53 189.1346 Creatinine-d3
ADMA 4.58 203.1503 > 46.0657 SDMA-d6
SDMA 4.74 203.1503 > 172.1086 SDMA-d6
SAH 5.37 385.1289 SDMA-d6
SAM 8.52 399.1445 SDMA-d6
Glutathione-13C215N 2.59 311.0954 –
Creatine-d3 2.54 135.0956 –
Creatinine-d3 3.23 117.0850 –
SDMA-d6 4.74 209.1879 > 175.1274 –
ﬁltration rate (GFR) and nephrological criteria based on comple-
mentary tests into stages CKD2 (60–89 mL/min/1.73 m2), CKD3
(30–59 mL/min/1.73 m2), CKD4 (15–29 mL/min/1.73 m2) and CKD5
(<15 mL/min/1.73 m2) of the disease [13]. In addition to the CKD
stage, information regarding age, sex, and whether they received
renal replacement therapy (dialysis or transplant) or not was avail-
able as well. For comparison purposes, 24 patients not suffering
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Table  2
Characteristics of the patients involved in the study.
CKD STAGE Characteristics of the population Number of patients (n)
SEX AGE TREATMENT
(M/F) (2–12 y/13–18 y) Not treated/Dialyzed/Transplanted
CONTROL 18/6 15/9 24/0/0 24
CKD2  8/6 10/4 9/0/5 14
CKD3  5/1 2/4 4/0/2 6
CKD4  2/4 3/3 5/0/1 6
CKD5  2/4 5/1 1/5/0 6
from chronic kidney disease aged 6–18 years were recruited for
the study (Table 2).
Blood samples were withdrawn in the morning after an
overnight fasting and were immediately cooled in an ice-water
bath. Then, they were centrifuged at 1000g for 5 min  at 4 ◦C. Sam-
ples were stored at −80 ◦C until sample treatment and analysis
were carried out [11].
The study protocol was approved by Cruces Hospital Ethics
Committee of Clinic Research and informed consent was given by
patients’ parents.
2.4. Sample treatment
First of all, samples were thawed and pooled plasma was made
of both control and CKD samples to be used after quantifying it by
standard additions to make a calibration curve in pooled plasma.
In addition, 50 L of plasma were placed in an Eppendorf tube to
quantify each plasma samples in triplicate. Plasma samples were
then spiked with 10 L of a mix  solution containing 15 g mL−1 of
creatinine-d3, creatine-d3, and glutathione-13C215N and 5 g mL−1
of SDMA-d6. Then, 50 L of dithiothreitol (77,000 mg  L−1) were
added and samples were incubated for 15 min  at room tem-
perature to perform the reduction of aminothiol compounds. In
addition, 150 L of cold acetonitrile were added to the mixture for
plasma protein precipitation and was vortexed before centrifuging
it for 10 min  at 13,000 rpm at 4 ◦C. The obtained supernatant was
then transferred to chromatographic vials, evaporated in nitrogen
stream and the residue was reconstituted in 200 L of ammonium
formate 5 mM.  Finally, these vials were transferred to autosampler
for the analysis by means of the LC-QTOF method.
2.5. Chemometric analysis
2.5.1. Multivariate analysis
Principal Component Analysis (PCA) was carried out on log-
arithm transformed, autoscaled data obtained from the analysis
of plasma samples with the developed LC-QTOF method. Matlab
R2015a (Mathworks, Natick, Massachusetts, United States) soft-
ware was used for performing the multivariate analysis. Outlying
samples were deﬁned according to Hierarchical Clustering with
single, complete and average linkage and removed.
We  compared several multivariate classiﬁcation methods in
their predictive ability for CKD, being Maximum Likelihood – Linear
Discriminant Analysis (ML-LDA) [14], Fisher-Linear Discriminant
Analysis (Fisher-LDA) [15], Quadratic Discriminant Analysis (QDA)
[16] and k Nearest Neighbours (kNN) [17]. For that purpose, a ran-
dom division of samples was done to obtain 80% of samples in a
training set and 20% of the samples in a test set, and leave-one-out
approach (LOO) was used on the training set to get the accuracy
for each classiﬁcation method. For kNN, it was necessary to select
the optimum number of neighbours to be used, which was  done
by testing different k numbers of neighbours from 1 to 10 using
LOO on the training set. The random division of the samples was
repeated 50 times and the mean performances obtained for each
classiﬁer and each parameter using the leave-one-out approach on
the training sets were used to compare the results.
Similarly, Partial Least Squares – Discriminant Analysis (PLS-DA)
[18] was  applied after optimizing the number of latent variables
(LV), and Sparse Partial Least Squares – Discriminant Analysis (sPLS-
DA) [19] after selecting the number of metabolites to be included.
In the case of sPLS-DA the number of latent variables was  selected
according to the number of groups minus one, as it is advised for
generating the most stable models.
Once the classiﬁcation method and the optimal parameters had
been selected, they were applied to the samples from the test set
and this operation was repeated 50 times to obtain the average
performance of the selected model. To judge whether the 15 amino
acids and related compounds measured improve the performance
and add to the CNN-based diagnosis, the optimized performance
of the classiﬁers were compared to the diagnostic performance by
CNN alone.
3. Results and discussion
3.1. Summary statistics
To have an approximate idea of the orders of magnitude of the
concentrations of the 16 metabolites analyzed in plasma, Fig. 2
shows an image made using Matlab R2015a (Mathworks Natick,
Massachusetts, United States) representing in a color scale the con-
centration of each analyte in each patient’s sample. In addition,
a table summarizing concentration levels of each amino acid in
plasma from both control and CKD pediatrics is showed in the same
ﬁgure.
This picture showed a big variation because even if almost all
of the compounds were expected to be within the range from 0
to 100 M,  some metabolites like CNN had concentrations up to
800 M1. After re-scaling the colors in the color bar of the image
from 0 to 100 M,  again 2 groups were differentiated: one con-
taining analytes from 30 to 100 M -and higher- (ARG, BET, CYS,
CIT, CTN, CNN, DMG, GLY, GSH, HARG, HCYS, and MET) and another
one containing metabolites approximately from 0 to 2 M (ADMA,
SDMA, SAH and SAM).
3.2. Multivariate analysis
3.2.1. Scaling and construction of PCA model
Multivariate data analysis tools take into consideration the
intrinsic interdependency of the metabolite concentrations. As
the concentrations of several metabolites were non-normally dis-
tributed across samples, logarithm transformation was  carried out.
Subsequently, autoscaling was  performed by normalizing the con-
centration of each metabolite in each sample by subtracting mean
metabolite concentration and dividing it by their standard devia-
tion. This scaling method assumes that all metabolites are equally
eligible to be important biomarkers, despite being present in higher
or lower concentrations in plasma. One CKD sample was  excluded
for being an outlier according to Single Linkage, Complete Linkage
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Fig. 2. Concentration of each amino acid per sample represented in a matrix according to a color scale (up) and a summary of the plasma concentrations for each metabolite
per  population group expressed as median and interquartile range in M (down).
and Average Linkage Hierarchical Clustering and was  also visible as
an outlier when doing Principal Component Analysis (PCA) plot.
This data pre-treatment enabled a separation between control
and CKD sample groups when doing PCA, as shown in the biplot in
Fig. 3. Moreover, the relation between sample groups and metabo-
lites can be obtained from the representation. SDMA, SAH, CNN,
SAM, CIT, ADMA, GSH, DMG  and GLY were found to be increased
in CKD patients comparing with control samples. The ﬁrst three
principal components account for 58% of variance.
The information obtained from PCA was compared with the
literature to check whether these up- or down-regulations could
be explained by any known mechanism. SDMA and ADMA are
thought to be increased due to the decreased excretion in renal
patients. Moreover, the reduced activity of ADMA catabolism by
dimethylarginine dimethylaminohydrolase (DDAH) would also be
responsible for the increase of ADMA [20]. Regarding high CIT and
GLY concentrations, low activity of the enzyme arginine/glycine
amidinotransferase (AGAT) could be suggested [21]. Similarly SAH
and SAM are thought to be increased in part due to impaired renal
clearance, as kidneys play a major role in aminothiol metabolism
[22]. Furthermore, it has been suggested that a reduction in the
ability to metabolize and/or excrete SAH could be a primary event
in CKD [23]. Several biomarkers of oxidative stress may  be elevated
in patients with CKD, such as glutathione [24], even if the nature
of the oxidative stress in these patients still remains unclear. This
impaired oxidative balance could be the result of increased reac-
tive oxygen species (ROS) production and reduced clearance, or due
to an ineffective antioxidant defense mechanism. Previous studies
had already shown increased total GSH increased levels in adults
suffering from CKD [25], but some other studies performed also in
adults showed the opposite [26] or no difference between healthy
and CKD patients [27]. Regarding DMG, it is a feedback inhibitor
of betaine-homocysteine methyltransferase enzyme, which is nor-
mally excreted in urine or metabolized to sarcosine [28]. Thus, it is
assumed that this increase could be related to accumulation, due to
an impaired urinary excretion, in addition to any unknown factor
that could also be involved.
The results of this unsupervised dimensionality reduction
matched quite well with the results obtained using univariate anal-
ysis based on Student’s t test for analytes with normal distribution
and U test in accordance to Mann and Whitney for those with
non-normal distribution after verifying the normal distribution of
samples using Kolmogorov-Smirnov test. Indeed, the mean values
of GLY, CIT, CNN, ADMA and SDMA were signiﬁcantly increased in
CKD patients when comparing with control individuals [11].
3.2.2. Classifying between early CKD and control samples using
all metabolites
In order to ﬁnd out whether any of these metabolites are inter-
esting as potential biomarkers for the early diagnosis of CKD,
a PCA model was constructed and a classiﬁcation method was
selected considering only early disease samples (those at CKD2
stage) and control samples (Fig. 4). Following these approaches,
not only the separation between groups was  complete except for
one CKD2 sample which was  placed with control samples, but
also an improvement in the performance of the classiﬁcation was
gained when using all the metabolites including CNN, in compari-
son with the single use of CNN. Indeed, after the optimization of
the classiﬁers, using all the metabolites with PLS-DA with 2 LV
the percentage of success was  76% and with sPLS-DA with 1 LV
and 4 metabolites was 67%. CIT, CNN, SAM, SDMA were the out-
put metabolites for sPLS-DA variable reduction and classiﬁcation
method. On the other hand, QDA was  selected as the best classiﬁ-
cation method when using only CNN with a performance of 71%.
Moreover, in order to have an idea of how well all non-CNN
metabolites performed in comparison with CNN, classiﬁcation was
also executed using the 15 metabolites, and a performance of 59%
was obtained using PLS-DA with 2 LV. Therefore, even if CNN alone
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Fig. 3. PCA biplot containing the score plot for control and CKD samples and the loading plot with the 16 amino acids for the ﬁrst 3 principal components.
Fig. 4. PCA biplot for control and early CKD samples (on the left) and the performances for different sample classiﬁcation methods (on the right).
is better than the rest of the metabolites for prediction purposes, the
rest of the metabolites could be useful biomarkers in combination
with CNN.
As a consequence, CIT, SAM and SDMA and CNN were found
to be the biologically relevant features according to the metabolite
selection carried out with sPLS-DA, and it would match with the fact
that CNN would be of special interest for classiﬁcation purposes in
comparison with the rest of the metabolites. Univariate statistical
analysis was  performed to verify if the two groups of samples were
signiﬁcantly different from each other for each of these 4 metabo-
lites. The univariate statistical analysis based on the use of Student’s
t-test for normal distributed metabolites and U test in accordance to
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Fig. 5. PCA for CNN, CIT, SAH and SDMA data for control and CKD samples regardless of the stage of the disease (left) and for control and early CKD samples (right).
Mann-Whitney for non-normal ones showed p-values below 0.001
for CIT, SDMA and CNN. Despite the fact that SAM did not have a
normal distribution and was not signiﬁcant according to the tests
(p > 0.05), median values and interquartile range showed slight dif-
ferences between both populations, in addition to a correlation of
SAM with SDMA (r = 0.92; p < 0.05), CIT (r = 0.74, p < 0.01) and CNN
(r = 0.77, p < 0.05). Thus, the use of a higher population is suggested
in order to clarify if there is any signiﬁcant difference between both
populations. Taking into account all of these evidences, it is worth
using only these four metabolites as an input to check the accuracy
of the different classiﬁers, described in the following sections.
3.2.3. Classifying between early CKD and control samples using
CIT, SAM, SDMA and CNN
The most practical approach and the one of special interest
would be to select the minimum number of metabolites capable
of increasing prediction accuracy compared to CNN alone, and if
possible also an increased one in comparison with using all the 16
metabolites. CNN, CIT, SAM and SDMA metabolites showed a simi-
lar efﬁciency for the early diagnosis of CKD in the output obtained
from sPLS-DA in comparison with the prediction of CNN alone, as
shown in the previous subsection. Furthermore, separation in the
PCA model of CKD and control groups was almost complete (Fig. 5)
and whether these metabolites used as an input could improve the
accuracy of classiﬁcation was checked as well. Once again, classi-
ﬁers were optimized for these 4 metabolites and a performance
of 89% was obtained using PLS-DA (LV = 1) for the classiﬁcation of
early CKD and control samples. This means an increase in perfor-
mance of 18% when using CIT, SAM and SDMA in addition to CNN
in comparison with using CNN only.
3.2.4. Stage-independent CKD diagnosis using all metabolites
Although the main objective of this work was to ﬁnd a few
potential biomarkers for early diagnosis, it is also interesting to
verify if these 16 metabolites could also be useful regardless of the
stage of CKD to be applicable in clinical practice. For that reason,
the same process was repeated for all the CKD samples, regardless
of the CKD stage using the 16 metabolites.
First of all, the various classiﬁcation methods were compared
and PLS-DA (LV = 1) with a classiﬁcation accuracy of 84% resulted in
the best outcome using all the metabolites including CNN, whereas
QDA was again the best classiﬁcation method using CNN alone to
sort the samples as control or CKD (81% performance). In both cases
performance was similar, so using all metabolites for classiﬁcation
would neither improve the accuracy in the diagnosis nor jeopardize
the performance.
3.2.5. Stage-independent CKD diagnosis using metabolites CIT,
SAM, SDMA and CNN
As CIT, SAM, SDMA and CNN provide the best results for the
early diagnosis of CKD, the classiﬁcation procedure was  repeated
using as input the concentration information for these metabolites
only in all the samples, regardless of the CKD stage. In this case,
PLS-DA (LV = 1) proved to be the best classiﬁer to be used and once
applied to the total amount of samples a performance of 91% was
achieved, thus enabling an improvement of 10% in comparison with
CNN alone.
Accordingly, metabolites CIT, SAM and SDMA might be of spe-
cial interest to add to CNN, as they improve the accuracy of CNN
diagnosis not only for early disease samples but also when using all
the samples, regardless of the CKD stage. Moreover, SDMA (r = 0.91,
p < 0.001), citrulline (r = 0.84, p < 0.001) and SAM (r = 0.77, p < 0.05)
were found to be correlated with CNN.
3.2.6. Classiﬁcation performance for CKD stages
Within the years different equations have been developed to
obtain the GFR with the aim of diagnosing those patients suffering
from CKD and to classify them according to the stage of the disease,
such as: Schwartz, Bedside Schwartz equation, Modiﬁcation of Diet
in Renal Disease (MDRD), Counahan-Barratt and Cockroft-Gault [4].
For the development of new equations “gold standards” like inu-
line, iohexol, iothalamate, 51Cr-EDTA or 99mTc-DTPA are commonly
used to obtain a real GFR value and to adjust the equations to get a
similar estimated GFR value based on the measurement of endoge-
nous metabolites. Despite being this the ideal, as a preliminary
study prior to the development of any new equation, metabolites
were evaluated using PCA and different classiﬁcation methods were
used to determine the stage of the disease.
Concerning the differences in metabolite proﬁle for different
CKD stages, PCA model obtained from using all the metabolites
showed that concentrations of some metabolites had increased
with disease severity, such as SAH, SAM, SDMA, ADMA,  CNN, CIT,
GSH and DMG, as shown in Fig. 6. Moreover, there was a complete
separation between the groups made of CTRL-CKD2 and CKD3 to
CKD5 groups. Likewise, including only CIT, SAM, SDMA and CNN
a good separation was  achieved and even in the case in which
CNN was not included, a gradation on CKD was observed (data
not shown). To check whether all the metabolites or some of them
could add, the accuracy of classiﬁcation using the plasma concen-
trations of the proposed metabolites was  compared with the use of
CNN concentration only. Some increase in performance was  found
using all the 16 metabolites including CNN with PLS-DA and 2 LV
(64%) and even a higher increase using CIT, SAM, SDMA and CNN
with PLS-DA and 2 LVs (74%), in comparison with using only CNN
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Fig. 6. PCA for all the metabolites showing the gradation of the samples according to the metabolite concentration and the stage of the CKD. In addition, the average confusion
matrix  for the best classiﬁer for all the metabolites in 50 different test sets is shown (up). Similarly PCA for the 4 selected metabolites and its corresponding confusion matrix
(down) are shown.
with QDA classiﬁcation (52%). Even if in general these accuracies do
not appear high, closer inspection of the confusion matrix shows
that almost all misclassiﬁcations occur one stage above or below
in comparison with the CKD stage assessed by the nephrologists
and less than 3% of the samples are misclassiﬁed 2 stages or more
above or below (Fig. 6). From a clinical point of view, misclassiﬁca-
tion of the samples into a different stage could affect the action plan
chosen for the patient. However, these recommended approaches
for each stage are general and do not change substantially when
classifying the samples one stage above or below.
It has to be taken into account that in our predictions clas-
siﬁcation performance using plasma CNN alone might be that
low because age, gender, height and/or weight of pediatrics are
commonly used in different equations to correct for some factors
affecting serum CNN concentration for the GFR calculation and
there is a chance that the classiﬁcation into the different CKD stages
could be improved by using these factors, instead of using CNN as
a linear predictor (Eq. (1)). For instance, Schwartz equation uses
height to correct for CNN production, as it is a function of muscle
mass which is related with body mass and among the variables of
body size tested by them, body length divided by CNN concentra-
tion provided the best correlation with GFR [29].
3.2.7. Age-, sex- and treatment-related effects
As mentioned before, it is necessary to check that the concen-
trations of these metabolites are not sex-related, age-related or
treatment-related, in case these effects are present to be able to
correct them in future equations, as it is done in Schwartz formula
(Eq. (1)). For this purpose, PCA using CIT, CNN, SAM and SDMA was
applied on the samples using two age groups ranging from 2 to
12 years old and from 13 to 18 years old, in agreement with the
division made by Way  et al., according to the normal GFR values
shown for children [30]. Although there was no clear separation of
the groups, some trend was  observed, as shown in Fig. 7. There-
fore, in order to ﬁnd any relation between age and metabolite
concentrations Partial Least Squares (PLS) regression method was
carried out to predict the age according to the metabolite levels in
plasma. No good prediction was  obtained when all samples or only
CKD samples were considered, whereas when only control samples
were considered the prediction was much better, thus meaning that
there is a positive correlation between age and metabolite concen-
trations in healthy pediatrics. The results were similar for either
using all the metabolites or using only CNN, SDMA, SAM and CIT as
variables.
Regarding sex, samples from both male and female groups were
overlapped in the score plot of the PCA, thus showing that there is
not any difference in metabolite concentrations according to sex.
This is something that could be expected since the patients were
pediatrics and no major differences in sex are presumed at these
ages. In addition, the same operation was  performed using only
adolescent samples, that is, those aged between 13 and 18 years
old. Nevertheless, no clear separation was observed neither using
all the metabolites nor the 4 selected ones.
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Fig. 7. On the left, PCA for all the samples with CIT, CNN, SAM and SDMA data, colored according to different age groups. On the right, a representation of a PLS regression
to  predict the age with all the samples, only control samples and only CKD samples.
Fig. 8. On the left, PCA with convex hull showing different distributions of samples according to the concentrations of CIT, CNN, SAM and SDMA and the relation with the
treatment received by CKD patient. On the right, sample distributions for control and transplanted patients.
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Besides, to check if there could be some effect on metabolite
concentration according to the treatment, PCA was  carried out for
untreated, transplanted and dialyzed CKD patients, but no separa-
tion was found between groups. However, transplanted patients
showed a more homogeneous amino acid proﬁle in comparison
with not treated and dialyzed ones (Fig. 8). Therefore, it could be
concluded that after receiving a transplant the amino acid proﬁle
tends to normalize and equalize. Moreover, if transplanted CKD
patients are compared to control patients, the distribution of the
samples is quite similar, thus implying that amino acid proﬁle
tends to equalize, even if both groups are still separated in PCA.
This means that amino acid proﬁles from controls and transplanted
patients have a similar distribution, but there are still some differ-
ences between both amino acid proﬁles.
This standardization in the metabolite concentration after trans-
plant could be expected as patients were transplanted when other
renal replacement therapy had failed and in all cases samples were
collected at least a year after having received the transplant.
4. Conclusions
Three new metabolites, CIT, SAM and SDMA, have been pro-
posed as potential biomarkers in addition to the commonly used
CNN to be implemented since they enable a better diagnosis of early
stages of CKD in pediatrics. Moreover, these metabolites showed
greater improvement also for the diagnosis of the rest of the stages
in CKD. In addition, some gradation in the concentration of these
metabolites according to the CKD stage has also been found. There-
fore, it is reasonable to think of including them in a new equation
to be used in general practitioners’ blood screening tests with some
other commonly used parameters as cystatin C protein concentra-
tion, CNN concentration, age, height and weight, in order to be
able to approximate the prediction of the disease performed by
nephrologitsts and to foresee the stage in CKD patients. In order to
comply with this purpose, it is suggested to collect a higher num-
ber of samples, to obtain GFR by using some contrast agent like
iohexol, which is used intravenously for radiologic procedures even
in the presence of renal disease, and which is not secreted, metab-
olized or reabsorbed by the kidneyfor future research. This would
allow adjusting a new equation for GFR calculation including CIT,
SDMA and SAM and comparing the performances obtained from
this equation with other commonly used equations like Schwartz
in pediatrics.
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